Biote Corp. (BTMD)

NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-10-23

$1.07-1.83%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Biote Corp.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
FY 2026 · Q4
Revenue	—	44.1M
EPS	—	0.023
FY 2026 · Annual
Revenue	$175M	178M
EPS	—	0.028
EBITDA	$25Mnon-GAAP	—
FY 2027 · Annual
Revenue	—	187.62M
EPS	—	0.238

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Adjusted EBITDA above $38 million in 2026	Profit targets include adjusted EBITDA above $38 million.	Broken	Adjusted EBITDA falls below $38 million in FY26	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Successful management of CEO transition	A supporting condition in Biote Corp.'s published investment case. The stated target is Interim CEO manages transition without disruption.	Under Pressure	Permanent CEO not appointed or leadership issues arise	No permanent CEO appointed Bob Peterson appointed interim CEO in May 2026; no permanent CEO appointed as of Oct 2026. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management context Stated as a priority in 2 of last 3 quarters. Leadership transition occurred in mid-2026 with Bob Peterson named Interim CEO. Management emphasizes continuity and operational discipline during transition. No direct financial impact cited but leadership stability is highlighted as critical to executing strategy. Delivery assessment Oct 24, 2026
Revenue above $190 million in 2026	Profit targets include adjusted EBITDA above $38 million.	Broken	Revenue falls below $190 million in FY26	Revenue: $44.232M FY2026-Q2; GAAP. Published target: >= $190 million. Target period is not explicitly aligned with this observation. Source published Aug 7, 202644,232,000 USD · source valueSource reportLast status assessment Oct 24, 2026 Measurement source consolidated · GAAP FY2026-Q2 · Period ending Jun 30, 2026 Source: company_financial_results. Reference: 22084d39-d3f9-4d07-8049-5df85751a42e. Source status: eligible. Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS: comparable history unavailable.

FY2027 revenue: comparable history unavailable.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	Unavailable	Unavailable	1 / 4
2026-07-25	Unavailable	Unavailable	1 / 4
2026-07-26	Unavailable	Unavailable	1 / 4
2026-07-27	Unavailable	Unavailable	1 / 4
2026-07-28	Unavailable	Unavailable	1 / 4
2026-07-29	Unavailable	Unavailable	1 / 4
2026-07-30	Unavailable	Unavailable	1 / 4
2026-07-31	Unavailable	Unavailable	1 / 4
2026-08-01	Unavailable	Unavailable	1 / 3
2026-08-02	Unavailable	Unavailable	1 / 4
2026-08-03	Unavailable	Unavailable	1 / 4
2026-08-04	Unavailable	Unavailable	1 / 4
2026-08-05	Unavailable	Unavailable	1 / 4
2026-08-06	Unavailable	Unavailable	1 / 4
2026-08-07	Unavailable	Unavailable	1 / 3
2026-08-08	Unavailable	Unavailable	1 / 3
2026-08-09	Unavailable	Unavailable	1 / 4
2026-08-10	Unavailable	Unavailable	1 / 3
2026-08-11	Unavailable	Unavailable	1 / 3
2026-08-12	Unavailable	Unavailable	1 / 4
2026-08-13	Unavailable	Unavailable	1 / 3
2026-08-14	Unavailable	Unavailable	1 / 3
2026-08-15	Unavailable	Unavailable	1 / 3
2026-08-16	Unavailable	Unavailable	1 / 3
2026-08-17	Unavailable	Unavailable	1 / 3
2026-08-18	Unavailable	Unavailable	1 / 3
2026-08-19	Unavailable	Unavailable	1 / 3
2026-08-20	Unavailable	Unavailable	1 / 3
2026-08-21	Unavailable	Unavailable	1 / 3
2026-08-22	Unavailable	Unavailable	1 / 3
2026-08-23	Unavailable	Unavailable	1 / 3
2026-08-24	Unavailable	Unavailable	1 / 3
2026-08-25	Unavailable	Unavailable	1 / 3
2026-08-26	Unavailable	Unavailable	1 / 3
2026-08-27	Unavailable	Unavailable	1 / 3
2026-08-28	Unavailable	Unavailable	1 / 3
2026-08-29	Unavailable	Unavailable	1 / 3
2026-08-30	Unavailable	Unavailable	1 / 3
2026-08-31	Unavailable	Unavailable	1 / 3
2026-09-01	Unavailable	Unavailable	1 / 3
2026-09-02	Unavailable	Unavailable	1 / 3
2026-09-03	Unavailable	Unavailable	1 / 3
2026-09-04	Unavailable	Unavailable	1 / 3
2026-09-05	Unavailable	Unavailable	1 / 3
2026-09-06	Unavailable	Unavailable	1 / 3
2026-09-07	Unavailable	Unavailable	1 / 3
2026-09-08	Unavailable	Unavailable	1 / 3
2026-09-09	Unavailable	Unavailable	1 / 3
2026-09-10	Unavailable	Unavailable	1 / 3
2026-09-11	Unavailable	Unavailable	1 / 3
2026-09-12	Unavailable	Unavailable	1 / 3
2026-09-13	Unavailable	Unavailable	1 / 3
2026-09-14	Unavailable	Unavailable	1 / 3
2026-09-15	Unavailable	Unavailable	1 / 3
2026-09-16	Unavailable	Unavailable	1 / 3
2026-09-17	Unavailable	Unavailable	1 / 3
2026-09-18	Unavailable	Unavailable	1 / 3
2026-09-19	Unavailable	Unavailable	1 / 3
2026-09-20	Unavailable	Unavailable	1 / 3
2026-09-21	Unavailable	Unavailable	1 / 3
2026-09-22	Unavailable	Unavailable	1 / 3
2026-09-23	Unavailable	Unavailable	1 / 3
2026-09-24	Unavailable	Unavailable	1 / 3
2026-09-25	Unavailable	Unavailable	1 / 3
2026-09-26	Unavailable	Unavailable	1 / 3
2026-09-27	Unavailable	Unavailable	1 / 3
2026-09-28	Unavailable	Unavailable	1 / 3
2026-09-29	Unavailable	Unavailable	1 / 3
2026-09-30	Unavailable	Unavailable	1 / 3
2026-10-01	Unavailable	Unavailable	1 / 3
2026-10-02	Unavailable	Unavailable	1 / 3
2026-10-03	Unavailable	Unavailable	1 / 3
2026-10-04	Unavailable	Unavailable	1 / 3
2026-10-05	Unavailable	Unavailable	1 / 3
2026-10-06	Unavailable	Unavailable	1 / 3
2026-10-07	Unavailable	Unavailable	1 / 3
2026-10-08	Unavailable	Unavailable	1 / 3
2026-10-09	Unavailable	Unavailable	1 / 3
2026-10-10	Unavailable	Unavailable	1 / 3
2026-10-11	Unavailable	Unavailable	1 / 3
2026-10-12	Unavailable	Unavailable	1 / 3
2026-10-13	Unavailable	Unavailable	1 / 3
2026-10-14	Unavailable	Unavailable	1 / 3
2026-10-15	Unavailable	Unavailable	1 / 3
2026-10-16	Unavailable	Unavailable	1 / 3
2026-10-17	Unavailable	Unavailable	1 / 3
2026-10-18	Unavailable	Unavailable	1 / 3
2026-10-19	Unavailable	Unavailable	1 / 3
2026-10-20	Unavailable	Unavailable	1 / 3
2026-10-21	Unavailable	Unavailable	1 / 3
2026-10-22	Unavailable	Unavailable	1 / 3
2026-10-23	Unavailable	Unavailable	1 / 3
2026-10-24	Unavailable	Unavailable	1 / 3

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	4	1
2026-06-01	4	1
2026-07-01	4	1
2026-08-01	4	1
2026-09-01	4	1
2026-10-01	4	1

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 4 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Adjusted EBITDA above $38 million in 2026Published status: Broken
Successful management of CEO transitionPublished status: Under Pressure
Revenue above $190 million in 2026Published status: Broken

Next proof point

Nov 4, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-65.0%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Biote Corp. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a recovery-focused healthcare business, with a sector tailwind but uneven company execution. The multi-year view is intact because recent financial performance remains in the top half of its industry, though the evidence for a durable recovery is still mixed.

What's priced into Biote Corp.

BTMD is rated cheap versus peers, and the valuation signal is marked as justified with low fragility. The evidence suggests expectations are not demanding, but confidence in that assessment is medium and does not remove the risk of weaker results.

What the fundamentals likely do

Near term, procedure revenue may improve sequentially in the second half of 2026, but management still expects year-over-year declines after the voluntary product recall. Adjusted EBITDA fell from the first to the second quarter, and full-year guidance was cut to above $25 million from $38 million. The recent earnings beat and stronger sector backdrop are positives, while high risk, erratic earnings surprises, and the CEO transition remain concerns.

What Biote Corp. hinges on

The key test is whether procedure revenue recovers and the company meets its revised 2026 EBITDA goal without another guidance cut. A weakening jobs report could add pressure to cyclical healthcare businesses, while continued strong results and guidance from sector bellwethers would support the sector backdrop. Leadership continuity also matters as the company works through its recovery.